References

Sanofi mRNA LNP Drug Product Continuous Manufacturing

The Challenge: The shift towards continuous bioprocessing present a transformative opportunity for LNP manufacturing. However, equipment engineering and automation need to be adapted.

The Solution: A combination of DIANT® Jet technology for nanoparticle production and RheaLyo™ Spin Freeze-Drying technology.

Resources:

Presentation by F. Peral, GMP Researcher, Sanofi, Waltham (MA) at the 9th Annual CCP Summit.

Bayer Spin-freezing Parameter Study

This study examines the impact of spin‑freezing parameters, as applied in the RheaLyo™ continuous spin-freeze-drying processes, on formulation composition and stability of a PEGylated peptide.

Formulation composition and storage temperature, rather than spin-freezing conditions, drive long-term stability.

Resources:

Schaal et al., International Journal of Pharmaceutics Volume 683, 15 October 2025, 126007

GSK Spin-freeze-drying of a live attenuated viral vaccine

The huge reduction in freeze-drying time (3 hours as opposed to 47 hours in the traditional batch procedure) is a striking benefit of continuous spin-freeze-drying. Furthermore, the comparable viral infectivity of spin- and batch-lyophilizates at T0 and following temperature stressing demonstrates that continuous spin-freeze-drying is a reliable alternative to the traditional batch freeze-drying process to preserve the long-term stability of viral vaccines.

Resources:

Poster CESPE conference 2023

Coriolis Pharma offers the RheaVita technology to its clients

Coriolis Pharma extends its service portfolio by integrating RheaVita’s Single Vial unit (SVU) technology for continuous and controlled freeze-drying to stabilize novel modalities as part of biologics drug product development for clients.

Resources:

Oral presentation by Maitê Harguindeguy, Scientist, “Advanced Freeze-Drying Technologies for Drug Product Development”, at The Pharma days Geneva 2025.